Targeting forkhead box M1 transcription factor in breast cancer.

Targeting forkhead box M1 transcription factor in breast cancer.
复制标题

DOI:
10.1016/j.bcp.2018.05.019
复制
发表时间:
2018-08
影响因子:
5.8
通讯作者:
Nahta R
Nahta R
中科院分区:
医学2区
文献类型:
--
作者:
O'Regan RM;Nahta R

文献摘要

参考文献

被引文献

相似文献

乳腺癌仍然是最常见的恶性肿瘤,也是美国妇女癌症相关死亡的第二大常见原因。对乳腺肿瘤分子异质性的进一步了解和多靶向治疗的批准已经彻底改变了乳腺癌患者的治疗前景和长期生存率。尽管开发了高效靶向药物,但耐药性和疾病进展仍然是临床关注的主要问题。对介导耐药的分子机制的进一步了解将有助于开发新的治疗方法。叉头盒M1 (FoxM1)转录因子在乳腺癌中过表达,并与靶向治疗和化疗的耐药密切相关。FoxM1调节癌症的所有特征,包括增殖、有丝分裂、EMT、侵袭和转移。抑制FoxM1转录因子功能是克服乳腺癌进展的潜在策略。在这篇研究更新中,我们回顾了FoxM1在乳腺癌中的作用以及阻断FoxM1转录因子功能的药理学方法。未来的临床前研究应评估抑制FoxM1功能和上游激酶信号通路的联合药物策略作为治疗耐药和转移性乳腺癌的潜在策略。
Breast cancer continues to be the most commonly diagnosed malignancy and second most common cause of cancer-related deaths among women in the United States. Improved understanding of the molecular heterogeneity of breast tumors and the approval of multiple targeted therapies have revolutionized the treatment landscape and long-term survival rates for patients with breast cancer. Despite the development of highly effective targeted agents, drug resistance and disease progression remain major clinical concerns. Improved understanding of the molecular mechanisms mediating drug resistance will allow new treatments to be developed. The forkhead box M1 (FoxM1) transcription factor is overexpressed in breast cancer and strongly associated with resistance to targeted therapies and chemotherapy. FoxM1 regulates all hallmarks of cancer, including proliferation, mitosis, EMT, invasion, and metastasis. Inhibition of FoxM1 transcription factor function is a potential strategy for overcoming breast cancer progression. In this research update, we review the role of FoxM1 in breast cancer and pharmacological approaches for blocking FoxM1 transcription factor function. Future preclinical studies should evaluate combination drug strategies to inhibit FoxM1 function and upstream kinase signaling pathways as potential strategies to treat resistant and metastatic breast cancers.
DOI: 10.1186/1471-2407-8-42
发表时间: 2008-02-06
期刊: BMC CANCER
影响因子: 3.8
作者:
Bektas, Nuran;ten Haaf, Anette;Veeck, Juergen;Wild, Peter Johannes;Luescher-Firzlaff, Juliane;Hartmann, Arndt;Knuechel, Ruth;Dahl, Edgar
通讯作者: Dahl, Edgar
DOI: 10.1016/j.ccr.2011.10.001
发表时间: 2011-11-15
期刊: Cancer cell
影响因子: 50.3
作者:
Anders L;Ke N;Hydbring P;Choi YJ;Widlund HR;Chick JM;Zhai H;Vidal M;Gygi SP;Braun P;Sicinski P
通讯作者: Sicinski P
DOI: 10.1371/journal.pone.0022217
发表时间: 2011
期刊: PloS one
影响因子: 3.7
作者:
Bolte C;Zhang Y;Wang IC;Kalin TV;Molkentin JD;Kalinichenko VV
通讯作者: Kalinichenko VV
DOI: 10.1159/000458156
发表时间: 2017-04-01
影响因子: 2.4
作者:
Abdeljaoued, Syrine;Bettaieb, Ilhem;Gamoudi, Amor
通讯作者: Gamoudi, Amor
DOI: 10.1016/s1470-2045(14)71159-3
发表时间: 2015-01-01
期刊: LANCET ONCOLOGY
影响因子: 51.1
作者:
Finn, Richard S.;Crown, John P.;Slamon, Dennis J.
通讯作者: Slamon, Dennis J.